Metformin May Not Improve Pancreatic Cancer Survival
Metformin, a common drug for type II diabetes, did not improve the survival of patients with pancreatic ductal adenocarcinoma.
Top Highlights From the 2015 AACR Annual Meeting
This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.
MM-302 Shows Promise in Heavily Pretreated HER2-Positive Breast Cancer
MM-302 showed encouraging efficacy results and a manageable safety profile in heavily pretreated HER2-positive metastatic breast cancer patients.
An Interview With AACR’s President-Elect
In this interview with ONCOLOGY Editor-in-Chief Nancy Davidson, MD, we dive into the “gray area” of breast biopsies and how the oncology community can meet this challenge. Dr. Davidson, AACR’s president-elect, also discusses the changes she has seen during her career with regard to how cancer patients are treated and looks forward during this optimistic time in treatment and research.
PD-1 Inhibition Shows Promise in Advanced NSCLC
April 22, 2015
Inhibition of PD-1 with pembrolizumab was well tolerated and showed promising survival results in a large phase I trial of patients with advanced non–small-cell lung cancer (NSCLC).
HPV Vaccine Can Protect Previously Exposed Patients
April 22, 2015
The HPV 16/18 vaccine protects women from cervical, anal, and oral HPV infections that can lead to cancer, including some women previously exposed to HPV.
Targeted Therapy Combo Shows Benefit in Breast and Ovarian Cancer
April 22, 2015
Combination treatment with the PARP inhibitor olaparib plus the PI3K inhibitor BKM120 showed a benefit in subsets of breast cancer and ovarian cancer patients.
Metastatic Prostate Cancer Patients Respond to PARP Inhibitor
April 21, 2015
Men with metastatic castration-resistant prostate cancer that had mutations in DNA repair genes were more likely to respond to the PARP inhibitor olaparib.
Nighttime Fasting Decreases Breast Cancer Risk
April 20, 2015
Women who spend less time eating each day and an increased amount of hours fasting overnight had a decreased risk of breast cancer.
MPDL3280A Shows Activity in Triple-Negative Breast Cancer
April 20, 2015
In an ongoing study, the immunotherapy MPDL3280A continues to be well-tolerated and to show signs of activity in triple-negative breast cancer patients.
